Biogen
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion. The acquisition, which centers on Apellis' pioneering therapies targeting
Apellis Pharmaceuticals
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive technical breakout followed the announcement that Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire the leader
Biogen
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion in cash. The deal, valued at $41 per
Biogen
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner, growth-oriented neurology powerhouse. Despite a 7% year-over-year revenue decline to $2.28 billion, the company beat Wall Street expectations
Biogen
Boston, MA – October 1, 2025 – Biogen Inc. (NASDAQ: BIIB) saw its stock surge by an impressive 9.02% today, propelled by a wave of promising advancements in its Alzheimer's disease drug testing pipeline. The significant leap signals renewed investor confidence and marks a potentially pivotal moment in the